Macrocytic Anemia (B12, Folate, MDS, Alcohol)

📋 Key Information Summary

📋

Macrocytosis is defined as a mean corpuscular volume (MCV) >100 fL on a full blood count (FBC); it affects approximately 2–4% of the Australian adult population and is more prevalent in older adults, heavy alcohol users, and those on antiretroviral or cytotoxic therapy.
The most common causes in Australia are excess alcohol intake, vitamin B12 (cobalamin) deficiency, folate deficiency, liver disease, hypothyroidism, and drug-induced macrocytosis (hydroxyurea, azathioprine, AZT, methotrexate, trimethoprim, mycophenolate).
A systematic approach begins with confirming true macrocytosis (MCV >100 fL), reviewing alcohol history, medication list, and thyroid function before ordering vitamin levels.
Serum vitamin B12 and folate are first-line tests; if serum B12 is borderline (150–250 pmol/L), methylmalonic acid (MMA) and homocysteine should be checked to confirm functional deficiency.
The peripheral blood smear is essential — look for macro-ovalocytes and hypersegmented neutrophils (≥5% neutrophils with ≥5 lobes) as hallmarks of megaloblastic anaemia.
Macrocytosis with concomitant cytopenias (bilineage or pancytopenia), dysplastic morphological features, persistent unexplained anaemia, or constitutional symptoms (weight loss, night sweats) should raise suspicion for myelodysplastic syndrome (MDS) and prompt urgent haematology referral.
B12 deficiency is treated with intramuscular hydroxocobalamin 1 mg on alternate days for 2 weeks, then every 2–3 months lifelong if due to pernicious anaemia or malabsorption; oral cyanocobalamin 1000 µg daily may be appropriate for dietary deficiency.
Folate deficiency is treated with folic acid 5 mg orally once daily for 4 months (or longer if malabsorption persists); always exclude and correct concurrent B12 deficiency before initiating folate to prevent neurological deterioration.
In Australia, hydroxocobalamin and cyanocobalamin injections are PBS-listed (Authority Required for ongoing pernicious anaemia); folic acid 5 mg tablets are available as a PBS General Benefit.
Aboriginal and Torres Strait Islander Australians, particularly those in remote and very remote communities, have higher rates of nutritional deficiency including folate and B12 deficiency; proactive screening, culturally safe health promotion, and folate supplementation in pregnancy are critical.
Macrocytosis in the setting of heavy alcohol use warrants concurrent liver function testing (LFTs), hepatitis serology, and assessment for alcoholic liver disease; alcohol-related macrocytosis is usually non-megaloblastic and improves with abstinence.
Special populations — pregnant women, elderly patients, those with gastrointestinal disease (coeliac, Crohn's, post-bariatric surgery), and patients on metformin or proton pump inhibitors — require heightened vigilance for B12 and folate deficiency.
Monitoring after treatment: reticulocyte count peaks at 7–10 days; repeat FBC at 8 weeks to confirm MCV normalisation; lifelong B12 injections for pernicious anaemia require regular review and monitoring for complications including gastric carcinoid risk.

Introduction & Australian Epidemiology

Macrocytic anaemia refers to anaemia (haemoglobin below the age- and sex-specific reference range) in which the mean corpuscular volume (MCV) exceeds 100 fL. The term "macrocytosis" describes an elevated MCV with or without accompanying anaemia and may be the earliest laboratory finding in several clinically significant conditions ranging from nutritional deficiency to myelodysplastic syndromes.

In Australian general practice, macrocytosis is a common incidental finding on full blood count (FBC), detected in approximately 2–4% of adults and up to 6–8% of patients aged over 65 years. The most frequent aetiologies mirror international patterns but carry a distinct Australian flavour: excessive alcohol consumption (responsible for up to 60% of macrocytosis cases in primary care), folate deficiency (historically improved by mandatory folate fortification of wheat flour for bread-making since 2009 under the Australia New Zealand Food Standards Code), vitamin B12 deficiency (particularly in older adults and those with pernicious anaemia), and drug-induced macrocytosis.

🇦🇺

Australian context — folate fortification: Since September 2009, mandatory folic acid fortification of wheat flour used for bread-making has been in effect in Australia under Food Standards Australia New Zealand (FSANZ) Standard 2.1.1. This has significantly reduced the prevalence of folate deficiency and neural tube defects but has not eliminated deficiency in high-risk groups including Aboriginal and Torres Strait Islander peoples, those with malabsorption, and heavy alcohol users.

The prevalence of pernicious anaemia (autoimmune-mediated B12 malabsorption) in Australia is estimated at 1–2% of the elderly population, with increasing recognition of subclinical deficiency. Vitamin B12 deficiency is particularly relevant in the Australian context given the ageing population, the high rates of proton pump inhibitor (PPI) and metformin use, and the presence of populations with limited access to animal-source foods.

Myelodysplastic syndromes (MDS) account for a smaller but clinically critical proportion of macrocytosis, particularly in patients over 60 years. In Australia, the annual incidence of MDS is approximately 4–5 per 100,000 population, rising to >30 per 100,000 in those aged over 80 years. Early identification of MDS through recognition of unexplained macrocytosis with cytopenias is essential for timely referral and management.

Aetiology	Mechanism	Approximate Proportion	Key Features
Alcohol excess	Direct marrow toxicity, folate depletion, liver disease	40–60%	Non-megaloblastic; MCV usually 100–110 fL; normalises with abstinence
Vitamin B12 deficiency	Impaired DNA synthesis	15–25%	Megaloblastic; may have neurological signs (subacute combined degeneration)
Folate deficiency	Impaired DNA synthesis	10–15%	Megaloblastic; improved since mandatory fortification; risk in pregnancy
Drug-induced	Variable — marrow suppression, DNA interference	10–15%	Hydroxyurea, AZT, methotrexate, azathioprine, mycophenolate, trimethoprim, phenytoin
Liver disease	Altered lipid membrane composition, spur cell formation	5–10%	Target cells on smear; deranged LFTs; often overlaps with alcohol
Hypothyroidism	Reduced erythropoietin, impaired folate metabolism	2–5%	Usually mild macrocytosis; corrects with thyroid hormone replacement
MDS / marrow disease	Clonal haematopoiesis, dysplastic erythropoiesis	2–5%	Persistent macrocytosis ± cytopenias; older age; dysplastic features on smear
Reticulocytosis	Large young red cells elevating MCV	Variable	Haemolytic anaemia, acute blood loss recovery; elevated reticulocyte count

Confirm Macrocytosis — MCV >100 fL

Macrocytosis is defined as an MCV exceeding 100 fL on an automated blood count analyser. Before pursuing an extensive work-up, the clinician must first confirm that the macrocytosis is genuine and not artefactual, and then systematically evaluate the most common and most dangerous causes.

Step 1 — Verify the Result

Check for cold agglutinins: in vitro red cell agglutination (e.g., Mycoplasma pneumoniae, Epstein-Barr virus) causes false elevation of MCV by the automated analyser. Warm the sample and repeat, or request a direct smear.
Marked hyperglycaemia (>30 mmol/L) can cause osmotic swelling of red cells and spurious macrocytosis.
Very high white cell counts (>50 × 10⁹/L) in leukaemia may interfere with the MCV measurement; this is less common with modern analysers but worth noting.
If MCV is 100–102 fL (borderline), consider repeating the FBC in 4–6 weeks rather than initiating an immediate work-up.

⚠️

Cold agglutinin trap: A patient presenting with unexpectedly high MCV, low RBC count, and normal or near-normal haemoglobin may have cold agglutinin disease causing in-vitro red cell clumping. Request the sample be warmed to 37°C and re-analysed, or examine the peripheral smear directly.

Step 2 — Clinical Context: Alcohol Intake

Excess alcohol consumption is the single most common cause of macrocytosis in Australian primary care. A thorough alcohol history using a validated tool is essential:

Use the AUDIT-C questionnaire or AUDIT (Alcohol Use Disorders Identification Test) to quantify consumption.
Men consuming >4 standard drinks per day or >14 per week, and women consuming >2 standard drinks per day or >7 per week, are at risk of alcohol-related macrocytosis.
Alcohol-related macrocytosis is typically non-megaloblastic with MCV 100–110 fL, normal B12 and folate levels, and elevated gamma-glutamyl transferase (GGT).
MCV usually normalises within 2–4 months of sustained abstinence.

Step 3 — Medication Review

Many commonly prescribed medications cause macrocytosis through various mechanisms. A systematic medication review should include:

Drug	Mechanism of Macrocytosis	Onset	Management
Hydroxyurea	Megaloblastic erythropoiesis via ribonucleotide reductase inhibition	2–4 months	Expected; do not discontinue for macrocytosis alone
Azathioprine / 6-mercaptopurine	DNA incorporation, megaloblastic change	2–6 months	Monitor; macrocytosis may be a marker of therapeutic effect in transplant patients
Methotrexate	Dihydrofolate reductase inhibition → folate depletion	Weeks to months	Consider folinic acid (leucovorin) supplementation; do NOT use folic acid if being used as chemotherapy
Zidovudine (AZT)	Mitochondrial toxicity, direct marrow suppression	2–8 weeks	Expected; assess for concurrent anaemia
Trimethoprim	Weak DHFR inhibition → functional folate depletion	Weeks to months	Usually mild; consider folate supplementation if symptomatic
Phenytoin / Phenobarbital / Primidone	Impaired folate absorption and metabolism	Months to years	Folic acid 5 mg daily; do not alter anticonvulsant dose without neurology input
Mycophenolate mofetil	Inosine monophosphate dehydrogenase inhibition	Weeks to months	Monitor FBC regularly; adjust dose if pancytopenia develops
Proton pump inhibitors (PPIs)	Reduced gastric acid → impaired B12 absorption	Years	Check B12 levels if long-term use (>2 years); supplement if deficient
Metformin	Reduced calcium-dependent B12-intrinsic factor absorption in terminal ileum	Months to years	Check B12 annually in long-term users; supplement if deficient

Step 4 — Thyroid Function

Hypothyroidism is a recognised cause of mild macrocytosis (typically MCV 100–110 fL) through reduced erythropoietin production and impaired folate metabolism. A thyroid-stimulating hormone (TSH) should be checked in all patients with unexplained macrocytosis, particularly those with symptoms of hypothyroidism (fatigue, weight gain, cold intolerance, constipation) or an established autoimmune condition.

Step 5 — Liver Disease

Liver disease, whether alcohol-related or from other aetiologies (non-alcoholic steatohepatitis, chronic viral hepatitis, autoimmune hepatitis), causes macrocytosis through altered membrane lipid composition. Patients with macrocytosis should have liver function tests (LFTs) checked including alanine aminotransferase (ALT), aspartate aminotransferase (AST), GGT, alkaline phosphatase (ALP), bilirubin, and albumin.

1

Verify MCV

Confirm genuine macrocytosis; exclude cold agglutinins, hyperglycaemia artefact

2

Alcohol & Medications

AUDIT-C assessment; comprehensive medication review including OTC and complementary medicines

3

Thyroid & Liver

TSH and LFTs (ALT, AST, GGT, ALP, bilirubin, albumin) in all patients with unexplained macrocytosis

4

Vitamin Levels

Serum B12 and folate; MMA and homocysteine if B12 is borderline (150–250 pmol/L)

Vitamin Level Testing

Once macrocytosis has been confirmed and the common non-nutritional causes (alcohol, medications, liver disease, hypothyroidism) have been evaluated, the next critical step is measurement of vitamin B12 and folate levels. In many cases, these causes coexist — for example, heavy alcohol users are often simultaneously B12 and folate deficient.

First-Line: Serum Vitamin B12 and Folate

Test	Reference Range	Interpretation	MBS Item
Serum vitamin B12 (cobalamin)	150–700 pmol/L (lab-dependent)	<150 pmol/L = deficient; 150–250 pmol/L = borderline; >250 pmol/L = adequate	MBS 66832
Serum folate	>7 nmol/L (lab-dependent)	<7 nmol/L = deficient; 7–14 nmol/L = low-normal; >14 nmol/L = adequate	MBS 66583
Red cell folate	>360 nmol/L (lab-dependent)	Reflects tissue folate stores (2–3 months); less affected by recent intake than serum folate; request if serum folate is borderline	MBS 66584

⚠️

Always check B12 before treating folate deficiency: Folic acid supplementation can mask the haematological manifestations of B12 deficiency (correcting the megaloblastic anaemia) while allowing neurological damage (subacute combined degeneration of the spinal cord) to progress silently. This is a critical safety concern, particularly in patients with pernicious anaemia.

Second-Line: MMA and Homocysteine (Functional B12 Markers)

When serum B12 is borderline (150–250 pmol/L) or there is strong clinical suspicion of B12 deficiency despite a low-normal serum level, functional markers should be ordered:

Available Methylmalonic acid (MMA) Serum MMA >0.4 µmol/L is elevated and indicates functional B12 deficiency. MMA is highly specific for B12 deficiency (B12 is a cofactor for methylmalonyl-CoA mutase). Elevated MMA can also occur in renal impairment — interpret with eGFR. MBS 66860.

Available Homocysteine Elevated in both B12 deficiency (B12-dependent methionine synthase) and folate deficiency (folate-dependent methionine synthase). Less specific than MMA. A normal homocysteine with normal MMA effectively excludes functional B12 deficiency. MBS 66633.

💡

Interpreting MMA and homocysteine together: Elevated MMA + elevated homocysteine → B12 deficiency. Normal MMA + elevated homocysteine → folate deficiency (or B6 deficiency, or renal impairment). Elevated MMA + normal homocysteine → consider renal impairment as cause of elevated MMA, or early B12 deficiency with adequate folate. Both normal → B12 deficiency unlikely.

Dietary and Malabsorption Risk Assessment

When B12 or folate deficiency is confirmed, a thorough dietary and malabsorption evaluation is essential to identify the underlying cause and guide treatment duration:

Dietary Causes of B12 Deficiency

Strict vegans and vegetarians (B12 is found almost exclusively in animal-derived foods: meat, fish, eggs, dairy).
Elderly patients with poor dietary intake or limited access to animal-source foods.
Patients with eating disorders or severe malnutrition.
Exclusively breastfed infants of B12-deficient mothers (vegan mothers, pernicious anaemia).

Malabsorption Causes of B12 Deficiency

Pernicious anaemia: Autoimmune destruction of gastric parietal cells → absent intrinsic factor. The most common cause of severe B12 deficiency in Australia. Diagnose with anti-intrinsic factor antibodies (highly specific, ~60% sensitive) and anti-parietal cell antibodies (~90% sensitive but less specific). Consider screening family members.
Gastric causes: Atrophic gastritis (Helicobacter pylori-related or autoimmune), post-gastrectomy / bariatric surgery (Roux-en-Y gastric bypass is a major cause of B12 malabsorption), chronic PPI use (>2 years).
Intestinal causes: Coeliac disease, Crohn's disease (particularly ileal involvement or post-terminal ileum resection), tropical sprue, small intestinal bacterial overgrowth (SIBO), chronic pancreatitis (impaired R-protein cleavage).
Drug-related: Metformin (reduces calcium-dependent B12-intrinsic factor absorption; up to 30% of long-term users develop low B12 levels), PPIs and H2-receptor antagonists (reduce gastric acid required to release B12 from food).

Causes of Folate Deficiency

Inadequate dietary intake (low fruit and vegetable consumption; alcohol dependence; elderly living alone).
Increased requirements: pregnancy, lactation, haemolytic anaemias (chronic haemolysis increases folate demand), exfoliative dermatitis.
Malabsorption: coeliac disease, tropical sprue, Crohn's disease.
Drug-induced: methotrexate, trimethoprim, phenytoin, phenobarbital, sulfasalazine.
Alcohol excess: impairs folate absorption, increases renal excretion, reduces hepatic storage.

Autoimmune Screening for Pernicious Anaemia

When B12 deficiency is confirmed and dietary intake appears adequate, test for:

Anti-intrinsic factor (IF) antibodies — specificity ~95–100%, sensitivity ~50–60%. The most useful confirmatory test for pernicious anaemia.
Anti-parietal cell (APC) antibodies — sensitivity ~90% but specificity ~50%. Positive in many autoimmune conditions. Useful if IF antibodies are negative but clinical suspicion is high.
Gastrin level — markedly elevated in autoimmune atrophic gastritis (secondary to loss of acid-secreting parietal cells). Not routinely required but may support diagnosis.

Peripheral Smear & Other Laboratories

The peripheral blood film is an indispensable adjunct to automated FBC results and should be requested in all cases of unexplained macrocytosis. It provides morphological information that cannot be derived from automated analysers and is essential for distinguishing megaloblastic from non-megaloblastic macrocytosis and for identifying features suggestive of MDS or haemolysis.

Key Morphological Findings

Finding	Description	Significance
Macro-ovalocytes	Large, oval-shaped red cells (MCV typically >110 fL)	Hallmark of megaloblastic anaemia (B12 or folate deficiency); also seen in MDS, liver disease
Hypersegmented neutrophils	≥5% of neutrophils with ≥5 lobes, or any neutrophil with ≥6 lobes	Highly specific for megaloblastic erythropoiesis; may be the earliest morphological change
Howell-Jolly bodies	Small, round, dark purple inclusions in red cells (nuclear remnants)	Normally removed by spleen; present in hyposplenism (consider coeliac disease, post-splenectomy)
Target cells	Bull's-eye appearance red cells	Liver disease, haemoglobinopathies (HbC, HbE, thalassaemia); if dominant feature, consider liver pathology
Schistocytes	Fragmented red cells (helmet cells, triangles)	Microangiopathic haemolytic anaemia (TTP, HUS, DIC); urgent referral
Sideroblasts	Ring sideroblasts on Prussian blue stain (bone marrow)	Sideroblastic anaemia — consider MDS-RS, lead poisoning, alcohol, isoniazid, pyridoxine deficiency
Dysplastic features	Nuclear-cytoplasmic asynchrony, abnormal granulation, Pelger-Huët-like cells	Suggestive of MDS — requires bone marrow biopsy for confirmation
Teardrop cells (dacrocytes)	Tear-shaped red cells	Myelofibrosis, other infiltrative marrow disorders; consider if splenomegaly present

🚨

Megaloblastic crisis — neurological emergency: Severe B12 deficiency (typically serum B12 <100 pmol/L) can present with pancytopenia and neurological features including peripheral neuropathy, ataxia, cognitive impairment, and subacute combined degeneration of the spinal cord (posterior column and corticospinal tract involvement). Neurological damage may be irreversible if B12 replacement is delayed. Initiate hydroxocobalamin immediately upon clinical suspicion while awaiting confirmatory results.

Supporting Laboratory Investigations

Essential Full blood count with differential & reticulocyte count Evaluate for pancytopenia (low Hb, WBC, platelets), isolated macrocytosis, or concurrent iron deficiency (which may mask macrocytosis by producing microcytic red cells — resulting in a "dimorphic" or normal MCV picture). Reticulocyte count helps distinguish underproduction (low reticulocytes) from haemolysis/blood loss (high reticulocytes). MBS 66512.

Essential Liver function tests (LFTs) ALT, AST, GGT, ALP, total and conjugated bilirubin, albumin. Deranged LFTs suggest liver disease as a cause of macrocytosis and may indicate concurrent alcoholic liver disease or hepatitis. GGT is particularly sensitive to alcohol intake. MBS 66515.

Essential Thyroid-stimulating hormone (TSH) Hypothyroidism is a reversible cause of macrocytosis. A normal TSH effectively excludes thyroid disease. MBS 66715.

Available Iron studies (ferritin, transferrin saturation, serum iron) Concurrent iron deficiency may mask macrocytosis by producing microcytes; combined deficiency can result in a normal MCV. Always check iron studies when macrocytosis is present to exclude a dimorphic blood picture. MBS 66600.

Available Direct antiglobulin test (Coombs test) If haemolysis is suspected (elevated reticulocytes, elevated LDH, low haptoglobin, indirect hyperbilirubinaemia). Autoimmune haemolytic anaemia can coexist with macrocytosis from other causes, or may itself cause macrocytosis via reticulocytosis. MBS 66556.

Available Lactate dehydrogenase (LDH) & haptoglobin LDH is elevated in both megaloblastic anaemia (ineffective erythropoiesis) and haemolysis. Haptoglobin is low in haemolysis but normal in megaloblastic anaemia — this distinction is diagnostically useful. MBS 66545 / 66628.

Available Hepatitis serology If LFTs are deranged or risk factors present: hepatitis B surface antigen (HBsAg), hepatitis C antibody (anti-HCV), hepatitis A IgM if acute presentation. MBS 69354 / 69365.

Specialist Bone marrow biopsy / aspirate Required when MDS or other marrow pathology is suspected: persistent unexplained macrocytosis with cytopenias, dysplastic features on peripheral smear, or suspicion of infiltrative disease. Perform at a haematology centre. Not required for routine nutritional deficiency work-up.

💡

The dimorphic blood picture: A patient with concurrent iron deficiency and B12/folate deficiency may have a normal or near-normal MCV because microcytic iron-deficient red cells and macrocytic megaloblastic red cells "average out." Always consider this in patients with risk factors for both deficiencies (e.g., coeliac disease, pregnancy, chronic GI blood loss with malabsorption). A blood film showing a dimorphic population (mixed microcytic and macrocytic cells) is the clue.

When to Suspect MDS or Marrow Disease

Myelodysplastic syndromes (MDS) are a group of clonal haematopoietic stem cell disorders characterised by dysplastic and ineffective blood cell production, peripheral cytopenias, and a variable risk of progression to acute myeloid leukaemia (AML). Unexplained, persistent macrocytosis may be the earliest — and sometimes only — laboratory abnormality in MDS, making its recognition critically important.

Red Flag Features — Triggers for Urgent Haematology Referral

🚨

Refer urgently to haematology if any of the following are present alongside macrocytosis:

Unexplained persistent macrocytosis (MCV >100 fL for >3 months) despite normal B12, folate, TSH, LFTs, and no attributable medication or alcohol cause.
Bicytopenia or pancytopenia (any combination of low Hb, neutrophils <1.5 × 10⁹/L, platelets <150 × 10⁹/L).
Persistent isolated neutropenia (neutrophils <1.5 × 10⁹/L) or thrombocytopenia (platelets <150 × 10⁹/L) with macrocytosis.
Dysplastic morphological features on peripheral smear (dysplastic neutrophils, pseudo-Pelger-Huët cells, micromegakaryocytes).
Constitutional symptoms: unexplained weight loss (>5% body weight over 6 months), drenching night sweats, recurrent fevers, bone pain.
Persistent unexplained macrocytosis in a patient aged >60 years without an obvious cause — MDS incidence increases sharply with age.
Isolated macrocytosis with a very high MCV (>120 fL) in the absence of severe B12/folate deficiency.

MDS Risk Stratification (IPSS-R — Revised International Prognostic Scoring System)

Once MDS is diagnosed (requiring bone marrow biopsy with aspirate, iron stain, cytogenetics, and flow cytometry), risk stratification using the IPSS-R guides management:

Very Low Risk

IPSS-R ≤1.5 points

Single lineage dysplasia, <5% marrow blasts, favourable cytogenetics, no significant cytopenias. Median survival >8 years.

Setting: Watch and wait; GP monitoring with haematology oversight

Low Risk

IPSS-R 1.5–3 points

One or two cytopenias, dysplasia in one or more lineages, favourable or intermediate cytogenetics. Median survival 5–8 years.

Setting: Haematology-led; supportive care; consider ESAs, G-CSF

Intermediate Risk

IPSS-R 3–4.5 points

Multilineage dysplasia, moderate cytopenias, intermediate cytogenetics. Median survival 3–5 years.

Setting: Haematology; consider lenalidomide (if del(5q)), hypomethylating agents (azacitidine)

High Risk

IPSS-R 4.5–6 points

Excess blasts (10–19%), unfavourable cytogenetics, multilineage cytopenias. Median survival 1.5–3 years.

Setting: Haematology; hypomethylating agents; consider allogeneic stem cell transplant if fit

Very High Risk

IPSS-R >6 points

Blasts 10–19% with adverse cytogenetics, or very complex karyotype. Median survival <1.5 years. High AML transformation risk.

Setting: Tertiary haematology; intensive treatment; transplant assessment

Other Marrow Diseases to Consider

Aplastic anaemia: Pancytopenia with a hypocellular marrow. May present with macrocytosis and progressive cytopenias. Autoimmune, drug-related, viral (parvovirus B19, hepatitis viruses), or idiopathic.
Myelofibrosis: Teardrop cells, leucoerythroblastic picture, massive splenomegaly. Check JAK2, CALR, MPL mutations.
Haematological malignancy: Acute leukaemia, lymphoma with marrow involvement, myeloma, or chronic myeloproliferative neoplasms may all present with macrocytosis and cytopenias.
Infiltrative marrow disease: Metastatic carcinoma (prostate, breast, lung), granulomatous disease (sarcoidosis, tuberculosis), or storage diseases can infiltrate the marrow and cause peripheral cytopenias with macrocytosis.
Copper deficiency: A rare but important cause of pancytopenia with macrocytosis mimicking MDS. Consider in patients with gastric surgery, zinc excess (which impairs copper absorption), or prolonged parenteral nutrition. Check serum copper and caeruloplasmin.

⚠️

Prior to bone marrow biopsy: Ensure B12, folate, copper, and thyroid function are all documented as normal, and that relevant medications have been reviewed. Nutritional deficiencies can produce striking dysplasia on marrow aspirate that is entirely reversible with supplementation. Documenting normal vitamin levels before biopsy avoids an unnecessary diagnostic procedure.

Treatment — Directed Therapy

Treatment of macrocytic anaemia is directed at the underlying cause. The following outlines the pharmacological management of the most common nutritional causes — B12 deficiency and folate deficiency — as well as management principles for drug-induced and alcohol-related macrocytosis.

Vitamin B12 Replacement

💊

Hydroxocobalamin

Cytamen® · Generic · Vitamin B12 analogue

Indication Pernicious anaemia, malabsorption, dietary B12 deficiency (severe), neurological B12 deficiency

Adult dose — loading 1 mg IM on alternate days for 2 weeks (i.e., 7 doses)

Adult dose — maintenance 1 mg IM every 2–3 months lifelong (for pernicious anaemia/malabsorption)

Paediatric dose Neonates/infants: 100–250 µg IM monthly; Children: 250–1000 µg IM monthly depending on age and weight

Route Intramuscular (IM); preferred over cyanocobalamin in Australia for established deficiency

Renal adjustment No adjustment required; MMA monitoring may be unreliable in CKD

Hepatic adjustment No adjustment required

Key side effects Injection site reactions; red discolouration of urine (harmless); rare anaphylaxis; hypokalaemia on initiation (monitor potassium in first 48 hours)

PBS status ✔ PBS Authority Required — Pernicious anaemia / documented malabsorption

💊

Cyanocobalamin

Generic · Vitamin B12

Indication Dietary B12 deficiency (mild-moderate), supplementation for vegans/vegetarians, metformin/PPI users

Adult dose — oral 1000 µg (1 mg) PO once daily for 3 months, then 100–250 µg daily for maintenance

Adult dose — IM 1000 µg IM on alternate days for 2 weeks, then monthly

Paediatric dose Oral: 100–500 µg daily depending on age; IM: as per hydroxocobalamin dosing

Key considerations Oral high-dose (1000 µg) can be effective even in pernicious anaemia (1–2% passive absorption) but is NOT first-line for severe deficiency or neurological involvement

PBS status ✔ PBS General Benefit (oral tablets); Authority Required (injection)

⚠️

Monitoring potassium after B12 initiation: Rapid resumption of erythropoiesis following B12 replacement can cause intracellular potassium uptake, leading to hypokalaemia. In severe cases this can be life-threatening. Check serum potassium within 48 hours of initiating B12 replacement in patients with severe anaemia (Hb <80 g/L) or cardiovascular comorbidities.

Folic Acid Replacement

💊

Folic Acid

Generic · Vitamin B9

Indication Folate deficiency (confirmed), prevention of neural tube defects in pregnancy, methotrexate-related folate depletion

Adult dose — treatment 5 mg PO once daily for 4 months (or until Hb and MCV normalise; longer if ongoing malabsorption)

Adult dose — prophylaxis in pregnancy 0.5 mg (500 µg) PO once daily, starting at least 1 month before conception and continuing through first trimester. 5 mg daily if high risk (previous NTD, anticonvulsant use, BMI >30, diabetes, coeliac disease)

Paediatric dose Neonates: 50–100 µg/kg/day PO; Children: age-dependent, typically 2.5–5 mg PO daily

Route Oral (preferred); IV/IM only if oral route unavailable or malabsorption severe

Renal adjustment No adjustment required

Hepatic adjustment No adjustment required

Key safety warning ALWAYS exclude and correct B12 deficiency before initiating folic acid — folate can mask B12 deficiency haematologically while allowing neurological damage to progress

PBS status ✔ PBS General Benefit

💊

Folinic Acid (Leucovorin)

Lucovorin® · Generic · Reduced folate

Indication Methotrexate toxicity rescue; adjunctive therapy for CNS toxoplasmosis; bypasses DHFR inhibition (unlike folic acid)

Adult dose — methotrexate toxicity 10–25 mg IV/IM/PO every 6 hours until methotrexate level <0.05 µmol/L

Adult dose — methotrexate adjunct 5–15 mg PO weekly (day after methotrexate) to reduce side effects

Key consideration Unlike folic acid, leucovorin does NOT require DHFR for activation and is therefore effective when methotrexate is inhibiting DHFR

PBS status ⚡ PBS Authority Required

Alcohol-Related Macrocytosis

Counselling and referral for alcohol reduction or cessation (use AUDIT score to guide intervention intensity).
Refer to local Drug and Alcohol Services (DAS) or GP shared-care alcohol programs where available.
Thiamine (vitamin B1) 100–300 mg PO daily — Wernicke's encephalopathy prevention in heavy drinkers.
MCV typically normalises within 2–4 months of sustained abstinence.
Check and correct concurrent B12 and folate deficiency (common in alcohol-dependent patients).
Manage alcoholic liver disease per current hepatology guidelines.

Drug-Induced Macrocytosis

Do NOT discontinue essential medications (hydroxyurea, immunosuppressants, antiretrovirals) solely because of macrocytosis — it is usually an expected and benign effect.
Monitor FBC regularly (every 3–6 months) to ensure macrocytosis is stable and no progressive cytopenias develop.
If macrocytosis is severe (MCV >120 fL) or accompanied by clinically significant cytopenias, discuss with the prescribing specialist before any medication adjustment.
Methotrexate-related macrocytosis: consider adding folinic acid (leucovorin) 5–15 mg weekly rather than folic acid.
Phenytoin-related macrocytosis: folic acid 5 mg daily is appropriate but should not alter seizure control; liaison with neurology.

Monitoring

Monitoring the response to treatment of macrocytic anaemia is essential to confirm the diagnosis, ensure adequate correction, and detect relapse early. The following framework applies to B12 and folate deficiency management:

Day 3–5 Check serum potassium (risk of hypokalaemia from rapid erythropoiesis). Monitor for symptoms of hypokalaemia (muscle weakness, cramps, arrhythmia).

Day 7–10 Reticulocyte count should peak (reticulocytosis indicates bone marrow response). If no reticulocyte response, reassess diagnosis (wrong deficiency? concurrent marrow disease? MDS?).

Week 2 Patient should report subjective improvement in energy and wellbeing. Neurological symptoms (paraesthesia, ataxia) may begin to improve but recovery is slower than haematological response.

Week 8 Repeat FBC. Expect: MCV trending toward normal (<100 fL), haemoglobin rising toward reference range. If MCV has not improved, consider: non-compliance, wrong diagnosis, concurrent deficiency (iron, B12 + folate), or MDS.

Month 3 Repeat FBC and vitamin levels (B12 and/or folate). Confirm MCV has normalised. For B12 deficiency from pernicious anaemia: confirm maintenance injection schedule is established.

Month 6 Review clinical response. Neurological improvement may take 6–12 months and may be incomplete if diagnosis was delayed. Repeat anti-IF antibodies not needed (remain positive regardless of treatment).

Ongoing — Lifelong Pernicious anaemia requires lifelong B12 injections every 2–3 months. Annual review: FBC, B12 level, clinical assessment. Consider annual serum gastrin or chromogranin A — pernicious anaemia carries a 2–3× increased risk of gastric carcinoid tumours and gastric adenocarcinoma. Discuss surveillance gastroscopy with gastroenterology.

💡

When MCV does not normalise after B12/folate replacement: Consider concurrent iron deficiency (dimorphic picture), alcohol excess, drug effect, liver disease, hypothyroidism, or MDS. If all reversible causes have been excluded and MCV remains persistently elevated >100 fL for >6 months, refer to haematology for bone marrow assessment.

Special Populations

🤰 Pregnancy

Folate requirements Increased demand: folic acid 0.5 mg daily for all women planning pregnancy or in the first trimester; 5 mg daily for high-risk women (previous neural tube defect, anticonvulsant use, BMI >30, diabetes, coeliac disease, multiple pregnancy).

B12 in pregnancy Deficiency risk increases with vegan/vegetarian diet, hyperemesis gravidarum, and pernicious anaemia. Untreated B12 deficiency is associated with neural tube defects, preterm birth, and low birth weight. Check B12 levels in high-risk women. Hydroxocobalamin is safe in pregnancy.

Macrocytosis in pregnancy Mild macrocytosis may be physiological. Always investigate if MCV >105 fL or if other cytopenias are present. Haemolysis (HELLP syndrome, TTP/HUS) must be excluded urgently in the third trimester.

👶 Paediatrics

Neonatal/infant B12 deficiency Exclusively breastfed infants of B12-deficient mothers (vegan mothers, pernicious anaemia, post-bariatric surgery) are at high risk. Present with failure to thrive, developmental delay, megaloblastic anaemia, and hyperpigmentation. Urgent B12 replacement: 100–250 µg IM daily for 5–10 days then monthly.

Childhood folate deficiency Uncommon in Australia since mandatory fortification. Consider in coeliac disease, inflammatory bowel disease, anticonvulsant use, haemolytic anaemias (hereditary spherocytosis, sickle cell disease, G6PD deficiency).

Drug-induced macrocytosis Common with methotrexate (juvenile idiopathic arthritis, leukaemia), azathioprine (transplant, IBD), and valproic acid. Monitor FBC regularly; macrocytosis is usually expected and benign.

MDS in children Rare. Consider inherited bone marrow failure syndromes (Fanconi anaemia, Diamond-Blackfan anaemia, Shwachman-Diamond syndrome). Paediatric haematology referral is essential.

👴 Elderly (>65 years)

Higher prevalence of macrocytosis Up to 6–8% of patients >65 years have MCV >100 fL. Causes: B12 deficiency (pernicious anaemia, atrophic gastritis, PPI/metformin use), alcohol excess, liver disease, MDS. Age alone does NOT explain macrocytosis — always investigate.

Pernicious anaemia Prevalence 1–2% in elderly. May present insidiously with fatigue, cognitive decline (pseudodementia), or subacute combined degeneration. Neurological features may precede haematological changes. Low threshold for B12 testing.

Metformin-related B12 deficiency Up to 30% of long-term metformin users (>4 years) develop low B12 levels. Annual B12 monitoring recommended. Supplement if B12 <200 pmol/L regardless of symptoms.

PPI-related B12 deficiency Chronic PPI use (>2 years) impairs B12 absorption from food. Consider B12 monitoring annually; switch to lowest effective dose or consider H2RA if appropriate. Do not discontinue PPI without clinical review (e.g., Barrett's oesophagus).

MDS risk Incidence increases sharply after age 60. Any unexplained persistent macrocytosis with cytopenias in an elderly patient warrants haematology referral.

🫘 Renal Impairment

Macrocytosis in CKD Chronic kidney disease can cause macrocytosis through uraemic toxins and erythropoietin deficiency. Erythropoiesis-stimulating agents (ESAs) do not typically cause macrocytosis.

B12 assessment in CKD MMA is renally cleared — elevated MMA in CKD may be spurious. Interpret B12 levels in context; homocysteine is also elevated in renal impairment. Rely more heavily on serum B12 level and clinical response to supplementation.

Dosing No renal dose adjustment for B12 or folic acid. Folic acid is water-soluble and renally excreted but toxicity is not a clinical concern.

🫁 Hepatic Impairment

Liver disease as a cause of macrocytosis Alcoholic and non-alcoholic liver disease commonly cause macrocytosis (target cells, spur cells, altered membrane lipid composition). MCV may be 100–120 fL.

Differentiating liver disease from B12 deficiency In liver disease: smear shows target cells (not macro-ovalocytes), LDH mildly elevated, haptoglobin normal. In B12 deficiency: macro-ovalocytes, hypersegmented neutrophils, markedly elevated LDH, MMA and homocysteine elevated.

Dosing No hepatic dose adjustment for B12 or folic acid. Treat underlying liver disease. Address alcohol cessation if applicable.

🛡️ Immunocompromised

HIV / antiretroviral therapy AZT (zidovudine) is a major cause of macrocytosis in HIV patients — it is actually a marker of drug adherence. Macrocytosis is expected and does not require intervention unless severe anaemia coexists. Other ART agents rarely cause macrocytosis.

Post-transplant patients Azathioprine and mycophenolate cause macrocytosis (expected). Macrocytosis may be a marker of therapeutic effect. Monitor FBC regularly for progressive cytopenias.

Patients on immunosuppressants Methotrexate (RA, psoriasis, transplant) causes macrocytosis via DHFR inhibition. Trimethoprim (prophylaxis in immunosuppressed) causes mild macrocytosis. Consider folinic acid supplementation for methotrexate users.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander Australians experience a disproportionate burden of nutritional deficiency, including folate and vitamin B12 deficiency, driven by intersecting social, environmental, and healthcare access factors. Macrocytic anaemia in this population requires culturally safe, community-informed approaches to screening, treatment, and follow-up.

Nutritional Deficiency Burden

Aboriginal and Torres Strait Islander Australians have higher rates of folate and B12 deficiency than the non-Indigenous population, particularly in remote and very remote communities where access to fresh animal-source foods (meat, dairy, eggs) and folate-rich fruits and vegetables may be limited by availability, cost, and supply chain reliability. Food insecurity affects approximately 24% of Aboriginal and Torres Strait Islander households compared to 4% of non-Indigenous households (AIHW 2023).

Folate Supplementation in Pregnancy

Neural tube defects remain more common in Aboriginal and Torres Strait Islander communities. Targeted folate supplementation campaigns (0.5 mg daily pre-conception and first trimester, 5 mg for high-risk women) must be delivered in a culturally appropriate manner through Aboriginal Community Controlled Health Organisations (ACCHOs), women's health programs, and remote area health services. Current NHMRC guidelines recommend all women of childbearing age in remote communities consider ongoing low-dose folate supplementation.

Remote & Very Remote Access

Specialist haematology services are limited in remote and very remote Australia. Patients in these areas rely on fly-in-fly-out (FIFO) visiting specialists, telehealth consultations via the Royal Flying Doctor Service (RFDS), and remote pathology services (e.g., Sonic Healthcare remote collection, Australian Clinical Labs outreach). Ensure timely B12 injection supplies are maintained in remote health clinics — missed injections due to supply gaps can cause severe relapse in pernicious anaemia.

Alcohol & FASD

Rates of alcohol-related harm are higher in some Aboriginal and Torres Strait Islander communities, though rates of non-drinking are also higher than the non-Indigenous population. Alcohol-related macrocytosis screening should be integrated with comprehensive alcohol brief intervention programs (e.g., AUDIT-C in primary care). Culturally safe referral pathways to Aboriginal Drug and Alcohol Workers and community-based healing programs are essential.

Chronic Disease Comorbidity

Aboriginal and Torres Strait Islander Australians have higher rates of chronic kidney disease, type 2 diabetes (with associated metformin use causing B12 deficiency), and chronic liver disease — all of which may cause or contribute to macrocytosis. Integrated, holistic chronic disease management through ACCHOs that includes regular FBC and nutritional screening is recommended.

Infectious Causes

Strongyloides stercoralis hyperinfection and chronic helminth infections are more prevalent in tropical and remote Aboriginal communities and may contribute to malabsorption and iron/folate deficiency. Consider stool microscopy and serology in patients from endemic areas with unexplained nutritional deficiency. Helicobacter pylori infection rates are higher and may contribute to atrophic gastritis and B12 malabsorption.

Cultural Safety in Clinical Care

Use culturally safe communication: avoid medical jargon; use interpreters for patients whose first language is not English (including Aboriginal English speakers); involve family and community Elders in care planning where appropriate; respect kinship systems and cultural obligations; deliver care through Aboriginal Health Workers and Practitioners (AHW/Ps) wherever possible. The RACGP's guide to providing care for Aboriginal and Torres Strait Islander patients provides practical frameworks.

📚 References

1. Green R, Dwyre DM. Evaluation of macrocytic anemias. Seminars in Hematology. 2015;52(4):279–286. doi:10.1053/j.seminhematol.2015.06.004
2. Stabler SP. Vitamin B12 deficiency. New England Journal of Medicine. 2013;368(2):149–160. doi:10.1056/NEJMcp1113996
3. Devalia V, Hamilton MS, Molloy AM; British Committee for Standards in Haematology. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. British Journal of Haematology. 2014;166(4):496–513. doi:10.1111/bjh.12959
4. Royal Australian College of General Practitioners (RACGP). Guidelines for Preventive Activities in General Practice (Red Book). 9th ed. Melbourne: RACGP; 2016 (updated 2023).
5. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework. Canberra: AIHW; 2023.
6. National Health and Medical Research Council (NHMRC). Nutrient Reference Values for Australia and New Zealand. Canberra: NHMRC; 2006 (updated 2023). Includes folate and B12 reference values.
7. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465. doi:10.1182/blood-2012-03-420489
8. Means RT. Myelodysplastic syndromes — recent biological advances and therapeutic implications. New England Journal of Medicine. 2023;389(14):1296–1308. doi:10.1056/NEJMra2300692
9. Food Standards Australia New Zealand (FSANZ). Standard 2.1.1 — Cereal and Cereal Products: Mandatory Folic Acid Fortification. Canberra: FSANZ; 2009.
10. Green R. Vitamin B12 deficiency from the perspective of a practicing hematologist. Blood. 2017;129(19):2603–2611. doi:10.1182/blood-2016-10-569186
11. Andrès E, Serraj K, Federici L, Vogel T, Kaltenbach G. Anemia in elderly patients: new insight into an old disorder. European Journal of Internal Medicine. 2010;21(5):367–372. doi:10.1016/j.ejim.2010.04.006
12. Snow CF. Laboratory diagnosis of vitamin B12 and folate deficiency: a guide for the primary care physician. Archives of Internal Medicine. 1999;159(12):1289–1298. doi:10.1001/archinte.159.12.1289
13. de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ. 2010;340:c2181. doi:10.1136/bmj.c2181
14. Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435–2442. doi:10.1001/jama.2013.280490
15. Haematology Society of Australia and New Zealand (HSANZ). Myelodysplastic Syndromes: Position Statement and Guidelines. Sydney: HSANZ; 2020.